Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study
evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by
coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II
Diabetes (T2DM) and atherosclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center